Conference Coverage

ECTRIMS/EAN statement on COVID-19 vaccination in patients with MS


 

FROM ECTRIMS 2021

Antibody testing is not currently recommended for assessing immunity following COVID vaccination because the clinical utility and serologic correlates of protection after vaccination have not been established. Antibody testing does not evaluate the cellular immune response, which may play a role in vaccine-mediated protection, according to the statement.


Vaccination strategy after COVID

People should be offered vaccination regardless of their history of symptomatic or asymptomatic COVID-19, including people with prolonged post-COVID symptoms. Data from clinical trials indicate that the currently authorized vaccines can be given safely to people with evidence of prior SARS-CoV-2 infection. For people who are known to be currently infected with SARS-CoV-2, vaccination should be deferred until the acute illness has passed.

Pregnancy/children

Data on the safety of COVID vaccines during pregnancy are limited. On the basis of current knowledge, experts believe that it is unlikely that COVID vaccines pose a risk to the pregnant person or fetus, and thus pregnant people with MS are eligible for and can receive a COVID-19 vaccine, the statement notes.

Adolescents aged 12-17 are eligible to receive the authorized mRNA vaccine, but children younger than 12 are not authorized to receive any COVID vaccine at this time, it adds.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Clinicians petition government for national quarantine
Covid ICYMI
Database will collect data on COVID-19 in patients with MS
Covid ICYMI
Lessons for patients with MS and COVID-19
Covid ICYMI
COVID-19 risks are no higher in patients with multiple sclerosis
Covid ICYMI
Guidance on additional COVID-19 vaccine dose for MS patients
Covid ICYMI
NIH to study COVID vaccine booster in people with autoimmune disease
Covid ICYMI
COVID-19 vaccination in MS: Lower response on certain medications
Covid ICYMI